3rd Floor

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Mittwoch, Mai 29, 2024
3rd Floor, Security (finance), File, Phase 3, Sale, Prospectus, Research, CNS, Central nervous system

The warrants have an exercise price of $1.455 per share, are immediately exercisable and will expire five years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $1.455 per share, are immediately exercisable and will expire five years following the date of issuance.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds to Reviva from this offering were approximately $3 million, before deducting the placement agent’s fees and other offering expenses.
  • A prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC.

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Retrieved on: 
Mittwoch, Mai 29, 2024
3rd Floor, Security (finance), Exercise, FDA, Therapy, Sale, Form, File, Immunotherapy, Venture round

The potential gross proceeds from the warrants, if fully exercised on a cash basis, will be approximately $10.0 million.

Key Points: 
  • The potential gross proceeds from the warrants, if fully exercised on a cash basis, will be approximately $10.0 million.
  • The securities described above were offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form F-3 (File No.
  • The offering was made only by means of the prospectus supplement that forms a part of such effective registration statement.
  • A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering has been filed with the SEC and may be obtained by visiting the SEC’s website located at www.sec.gov.

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Retrieved on: 
Dienstag, Mai 28, 2024
3rd Floor, Security (finance), FDA, Therapy, Sale, Form, File, Immunotherapy, Venture round

The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $5.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form F-3 (File No.
  • The offering of such securities in the registered direct offering is being made only by means of a prospectus supplement that forms a part of such effective registration statement.

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Dienstag, Mai 28, 2024
3rd Floor, Security (finance), File, Phase 3, Sale, Prospectus, Research, CNS, Central nervous system

The closing of the offering is expected to occur on or about May 29, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about May 29, 2024, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds to Reviva from this offering are expected to be approximately $3 million, before deducting the placement agent’s fees and other offering expenses.
  • A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC.

Pintec Filed 2023 Annual Report on Form 20-F

Retrieved on: 
Dienstag, April 30, 2024
Jinghai District, Republic, 3rd Floor, Security (finance), ADS, Eastern Time Zone, Annual report

BEIJING, April 30, 2024 /PRNewswire/ -- Pintec Technology Holdings Limited (NASDAQ: PT) ("Pintec" or the "Company"), is a Nasdaq-listed company providing technology enabled financial and digital services to micro, small and medium enterprises in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission ("SEC") on April 30, 2023 Eastern Time.

Key Points: 
  • BEIJING, April 30, 2024 /PRNewswire/ -- Pintec Technology Holdings Limited (NASDAQ: PT) ("Pintec" or the "Company"), is a Nasdaq-listed company providing technology enabled financial and digital services to micro, small and medium enterprises in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission ("SEC") on April 30, 2023 Eastern Time.
  • The annual report can be accessed on the Company's investor relations website at ir.pintec.com or the SEC's website at www.sec.gov .
  • The Company will provide hard copies of its annual report, free of charge, to its shareholders and ADS holders upon request.
  • Requests should be directed to the Company's Investor Relations Department at Pintec Technology Holdings Limited, 3rd Floor, No.11 Building, No.109 Yard Tianjizhigu, Jinghai 3rd Street, BDA, Beijing, People's Republic of China.

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Retrieved on: 
Dienstag, April 30, 2024
Sale, Prospectus, 3rd Floor, Security (finance), Public expenditure, Exercise, Telephone

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The aggregate gross proceeds to the Company from the offering were approximately $15 million, before deducting the placement agent fees and other offering expenses payable by the Company.
  • Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.
  • The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Mustang Bio Announces Closing of $4 Million Public Offering

Retrieved on: 
Donnerstag, Mai 2, 2024
Sale, Prospectus, 3rd Floor, A-3, Security (finance), Form, Exercise, Translation, Series, Cancer

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, and prior to any potential warrant exercises, were approximately $4 million.
  • The Company intends to use the net proceeds from this offering for working capital and general corporate and other purposes.
  • The offering was made only by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement.

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Retrieved on: 
Montag, April 22, 2024
Sale, Prospectus, Ovarian cancer, Warrant, GTG, Regulation D, Health, 3rd Floor, ASX, Research, Genetic testing, Form, ADS, American depositary receipt, B2B, Security (finance)

MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at an offering price of US$2.00 per ADS.

Key Points: 
  • The gross proceeds to the Company from this offering were approximately US$2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering were made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering were filed with the SEC.
  • Authorised for release by the Board of Directors of Genetic Technologies Limited.

PainReform Announces Closing of $4 Million Public Offering

Retrieved on: 
Donnerstag, April 18, 2024
Sale, Prospectus, TEL, 3rd Floor, Security (finance), Form, Therapy

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were $4 million.
  • The Company intends to use the net proceeds from this offering to advance the Company’s clinical studies, and for general corporate purposes.
  • The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Genetic Technologies Announces $2 Million Registered Direct Offering

Retrieved on: 
Donnerstag, April 18, 2024
Sale, Prospectus, Ovarian cancer, Warrant, GTG, Regulation D, Health, 3rd Floor, ASX, Research, Genetic testing, Form, ADS, American depositary receipt, B2B, Security (finance)

The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from this offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.